# reload+after+2024-01-20 02:43:21.706590
address1§1400 Sierra Point Parkway
address2§Building C Suite 200
city§Brisbane
state§CA
zip§94005
country§United States
phone§650 822 5500
fax§650 636 9773
website§https://www.annexonbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
fullTimeEmployees§76
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Douglas  Love Esq., J.D.', 'age': 55, 'title': 'CEO, President & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 921987, 'exercisedValue': 0, 'unexercisedValue': 607598}, {'maxAge': 1, 'name': 'Ms. Jennifer  Lew', 'age': 50, 'title': 'Executive VP, CFO & Corporate Secretary', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 624195, 'exercisedValue': 0, 'unexercisedValue': 13124}, {'maxAge': 1, 'name': 'Mr. Michael  Overdorf M.B.A.', 'age': 53, 'title': 'Executive VP & Chief Business Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 580469, 'exercisedValue': 0, 'unexercisedValue': 13124}, {'maxAge': 1, 'name': 'Dr. Arnon  Rosenthal Ph.D.', 'age': 67, 'title': 'Founder', 'yearBorn': 1956, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Dean R. Artis Ph.D.', 'age': 62, 'title': 'Chief Scientific Officer & Executive VP', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Miriam  Mason', 'title': 'Senior Vice President of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ted  Yednock Ph.D.', 'age': 65, 'title': 'Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 614596, 'exercisedValue': 0, 'unexercisedValue': 875987}, {'maxAge': 1, 'name': 'Henk-Andre  Kroon M.D.', 'title': 'Senior Vice President of Translational Medicine', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Jamie  Dananberg M.D.', 'age': 65, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§6
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.995
currency§USD
dateShortInterest§1702598400
forwardEps§-1.83
pegRatio§-0.07
exchange§NMS
quoteType§EQUITY
shortName§Annexon, Inc.
longName§Annexon, Inc.
firstTradeDateEpochUtc§1595597400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§39e86d0b-392a-371c-9e14-996bb9ee6158
gmtOffSetMilliseconds§-18000000
targetHighPrice§30.0
targetLowPrice§6.0
targetMeanPrice§13.83
targetMedianPrice§12.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§9.626
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
